company background image
153 logo

Anhui Fengyuan Pharmaceutical SZSE:000153 Stock Report

Last Price

CN¥7.77

Market Cap

CN¥2.5b

7D

-3.4%

1Y

-17.0%

Updated

27 Mar, 2024

Data

Company Financials

Anhui Fengyuan Pharmaceutical Co., Ltd.

SZSE:000153 Stock Report

Market Cap: CN¥2.5b

153 Stock Overview

Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells biopharmaceuticals, chemical pharmaceuticals, Chinese patent medicines, Chinese herbal decoction pieces, and APIs primarily in China.

153 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health4/6
Dividends3/6

Anhui Fengyuan Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anhui Fengyuan Pharmaceutical
Historical stock prices
Current Share PriceCN¥7.77
52 Week HighCN¥11.16
52 Week LowCN¥5.96
Beta0.74
1 Month Change1.70%
3 Month Change-16.45%
1 Year Change-16.99%
3 Year Change9.13%
5 Year Change9.59%
Change since IPO-8.88%

Recent News & Updates

Recent updates

Shareholder Returns

153CN PharmaceuticalsCN Market
7D-3.4%-3.4%-2.2%
1Y-17.0%-11.4%-14.8%

Return vs Industry: 000153 underperformed the CN Pharmaceuticals industry which returned -11.4% over the past year.

Return vs Market: 000153 underperformed the CN Market which returned -14.8% over the past year.

Price Volatility

Is 153's price volatile compared to industry and market?
153 volatility
153 Average Weekly Movement6.6%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement8.1%
10% most volatile stocks in CN Market11.4%
10% least volatile stocks in CN Market5.1%

Stable Share Price: 000153 has not had significant price volatility in the past 3 months.

Volatility Over Time: 000153's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19974,654n/ahttps://www.bbcayy.com

Anhui Fengyuan Pharmaceutical Co., Ltd. researches and develops, produces, and sells biopharmaceuticals, chemical pharmaceuticals, Chinese patent medicines, Chinese herbal decoction pieces, and APIs primarily in China. It offers products in various categories, which includes gynecology, respiratory system, hormonal, antipyretic analgesic, mental class, antiviral class, antibiotic class, oral anesthetic, masks class, urinary, water electrolyte balance, digestive system, cardiovascular class, Yinpian class, and nutrition and metabolism, as well as provides raw material drugs. The company also exports its products to Africa, Southeast Asia, Central Asia, Europe, and internationally.

Anhui Fengyuan Pharmaceutical Co., Ltd. Fundamentals Summary

How do Anhui Fengyuan Pharmaceutical's earnings and revenue compare to its market cap?
153 fundamental statistics
Market capCN¥2.54b
Earnings (TTM)CN¥160.15m
Revenue (TTM)CN¥4.30b

16.1x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
153 income statement (TTM)
RevenueCN¥4.30b
Cost of RevenueCN¥3.15b
Gross ProfitCN¥1.15b
Other ExpensesCN¥989.42m
EarningsCN¥160.15m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Apr 26, 2024

Earnings per share (EPS)0.48
Gross Margin26.72%
Net Profit Margin3.72%
Debt/Equity Ratio37.8%

How did 153 perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

21%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.